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Abstract: Obesity and its related metabolic abnormalities, including insulin resistance, 
alterations in the insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) axis, and 
the state of chronic inflammation, increase the risk of colorectal cancer (CRC) and 
hepatocellular carcinoma (HCC). However, these findings also indicate that the metabolic 
disorders caused by obesity might be effective targets to prevent the development of   
CRC and HCC in obese individuals. Green tea catechins (GTCs) possess anticancer and 
chemopreventive properties against cancer in various organs, including the colorectum and 
liver. GTCs have also been known to exert anti-obesity, antidiabetic, and anti-inflammatory 
effects, indicating that GTCs might be useful for the prevention of obesity-associated 
colorectal and liver carcinogenesis. Further, branched-chain amino acids (BCAA), which 
improve protein malnutrition and prevent progressive hepatic failure in patients with 
chronic liver diseases, might be also effective for the suppression of obesity-related 
carcinogenesis because oral supplementation with BCAA reduces the risk of HCC in obese 
cirrhotic patients. BCAA shows these beneficial effects because they can improve insulin 
resistance. Here, we review the detailed relationship between metabolic abnormalities and 
the development of CRC and HCC. We also review evidence, especially that based on our 
basic and clinical research using GTCs and BCAA, which indicates that targeting 
metabolic abnormalities by either pharmaceutical or nutritional intervention may be an 
effective strategy to prevent the development of CRC and HCC in obese individuals. 
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1. Introduction 
Obesity, which is the result of a positive energy balance, is a serious health problem throughout the 
world. The World Health Organization (WHO) estimates that currently, more than 1.5 billion adults 
worldwide are overweight, of which at least 500 million are obese [1]. Obesity is linked to several health 
disorders such as cardiovascular disease, hypertension, diabetes mellitus, and hyperlipidemia, which are 
collectively known as “metabolic syndrome”. In addition, mounting evidence indicates that obesity and 
its related metabolic abnormalities, especially diabetes mellitus, are associated with the development of 
certain types of human epithelial malignancies, including colorectal cancer (CRC) and hepatocellular 
carcinoma (HCC) [2–8]. On the basis of systematic reviews of epidemiological evidence as well as 
mechanistic interpretations and data from animal experimental models, the World Cancer Research 
Fund and American Institute for Cancer Research released a report in 2007 on the causal relationship 
between high body fatness and an increased risk of CRC [9]. A large-scale meta-analysis (221 datasets 
on 282,000 incidence cases) also revealed that the magnitude of risk for CRC was greater among obese 
men than non-obese men [10]. In a prospectively studied population of more than 900,000 American 
adults, the body mass index (BMI) was found to be significantly associated with higher rates of death 
from cancer, especially HCC, because the relative risk of death from HCC was significantly higher 
(4.52 times) among men with a BMI of at least 35.0 than those who had normal weight (95% 
confidence interval, 2.94–6.94) [11]. 
Several pathophysiological mechanisms that link obesity and colorectal and liver carcinogenesis 
have been shown, including the emergence of insulin resistance, alterations in the insulin-like growth 
factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) axis, the state of chronic inflammation, induction of oxidative 
stress, and occurrence of adipocytokine imbalance [2–6]. On the other hand, these findings also suggest 
that targeting these pathophysiological disorders via nutritional or pharmaceutical intervention might 
be an effective and promising strategy to inhibit obesity-related carcinogenesis. For instance,   
a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pitavastatin, which is 
widely used to treat hyperlipidemia, prevents obesity-related colorectal and liver carcinogenesis by 
attenuating chronic inflammation [12,13]. Captopril and telmisartan, which are anti-hypertensive drugs, 
also suppress the development of colonic preneoplastic lesions in obese and diabetic mice, and this 
suppression is associated with the reduction of oxidative stress and chronic inflammation [14]. 
In recent years, green tea catechins (GTCs) have received considerable attention because of their 
beneficial effects: they improve metabolic abnormalities and prevent cancer development [15–19]. 
Dietary supplementation with branched-chain amino acids (BCAA; leucine, isoleucine, and valine), 
which can prevent progressive hepatic failure in patients with chronic liver disease by improving 
insulin resistance [20–22], also reduces the risk of HCC in such patients who are obese [8]. In this 
article, we review the many mechanisms by which obesity and the related metabolic abnormalities 
influence the development of CRC and HCC while especially focusing on the emergence of insulin Int. J. Mol. Sci. 2012, 13                 
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resistance and the subsequent inflammatory cascade. We also prove that the nutraceutical approach 
using GTCs and BCAA might be effective in preventing obesity-related carcinogenesis in both the 
colorectum and liver. 
2. Potential Pathophysiological Mechanisms Linking Obesity and the Development of CRC 
Obesity is the main determinant of insulin resistance and hyperinsulinemia, which is a risk factor 
for CRC [23]. Insulin itself and the signal transduction network it regulates have important roles in 
oncogenesis [24,25]. In animal models, insulin stimulates the growth of CRC cells while also promoting 
CRC tumor growth [26,27]. In addition, insulin resistance increases the biological activity of IGF-1,  
an important endocrine and paracrine regulator of tissue growth and metabolism. The binding of 
insulin and IGF-1 to the cell-surface receptors, insulin receptor and IGF-1R, respectively, on tumors 
and precancerous cells activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which is 
responsible for cellular processes like growth, proliferation, and survival [24,25]. Alterations in the 
IGF/IGF-1R axis caused by insulin resistance contribute to the development of CRC [28]. IGF-1 is 
positively correlated with body fat and waist circumference [29]. Moreover, insulin resistance and 
increased adipose mass create an oxidative environment in the tissues that upregulates the expression 
of various pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-6 
(IL-6), which stimulate tumor growth and progression [30–34]. Increased oxidative stress promotes 
damage to cell structures, including DNA, and activates the PI3K/Akt pathway, and both these 
processes play a key role in cancer development [35,36]. Therefore, insulin resistance and the 
subsequent inflammatory cascade involving increased oxidative stress are regarded as important 
factors in the development of obesity-associated CRC. 
Excess production of storage lipids causes an adipocytokine imbalance, which entails increased 
levels of leptin and decreased levels of adiponectin in the serum, for example. This imbalance may 
also be related to obesity-associated carcinogenesis [37,38]. Leptin stimulates cell growth in CRC [39]. 
An epidemiologic study by Stattin et al. [40] suggested an association between circulating leptin levels 
and the development of CRC. TNF-α and IL-6 increase the levels of leptin, while leptin influences 
inflammatory responses, possibly by triggering the release of TNF-α and IL-6 [41–43]. These findings 
suggest that the pathophysiological abnormalities caused by obesity cooperatively aggravate the risk of 
cancers, including CRC, in obese individuals (Figure 1). Int. J. Mol. Sci. 2012, 13                 
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Figure 1. Proposed mechanisms linking obesity and its related metabolic abnormalities to 
the development of colorectal cancer (CRC) and hepatocellular carcinoma (HCC). 
 
3. Potential Pathophysiological Mechanisms Linking Obesity, Non-Alcoholic Fatty Liver 
Disease/Non-Alcoholic Steatohepatitis, and the Development of HCC 
Several pathophysiological mechanisms linking obesity, steatosis, and liver carcinogenesis have 
been shown, including insulin resistance and the subsequent inflammatory cascade. Insulin induces 
HCC cells to proliferate and resist apoptosis [44,45]. Insulin resistance raises the risk for recurrence  
of HCC after curative radiofrequency ablation in hepatitis C virus-positive patients [46]. Insulin 
resistance also leads to an increased expression of TNF-α and its dysregulation is associated with the 
development of steatosis and inflammation within the liver [47]. Activation of the IGF/IGF-1R axis  
is involved with liver carcinogenesis [48,49]. High levels of serum leptin, which stimulates the growth 
of HCC cells [50], increase the risk of HCC recurrence after curative treatment [51]. These findings 
suggest that in addition to colorectal carcinogenesis, obesity and its related metabolic abnormalities 
also play an important role in the development of HCC (Figure 1). 
Non-alcoholic fatty liver disease (NAFLD), which is known to be a hepatic manifestation of 
metabolic syndrome, is the most common form of chronic liver disease in developed countries [52,53]. 
It covers a spectrum of disorders ranging from simple steatosis to non-alcoholic steatohepatitis 
(NASH), which can progress to cirrhosis and thus HCC (Figure 1) [52,53]. Retrospective data suggest 
that in as many as 4–27% of cases, NASH progresses to HCC after cirrhosis develops [53,54]. Insulin 
resistance is considered a critical factor in the etiology of NASH [55]. The flux of free fatty acids  
to the liver and insulin resistance lead to hepatic fat accumulation, which causes inflammatory changes 
in the liver  [56,57]. Enhanced TNF-α expression and increased leptin levels are also found in   Int. J. Mol. Sci. 2012, 13                 
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patients with NASH [58,59]. In addition, Wong et al. [60] recently reported interesting results from a 
cross-sectional study, indicating that NASH is associated with a high prevalence of colorectal 
adenomas and advanced neoplasms. This finding may suggest that in addition to HCC, NASH may be 
associated with an increased risk of CRC. 
4. Preventive Effects of GTCs on the Metabolic Abnormalities and Cancer Development 
Numerous studies have indicated that tea catechins, especially GTCs, are beneficial for various 
reasons, such as their anti-obesity effects [15]. A recent meta-analysis of clinical trials reported that 
GTCs help reduce body weight [61]. The underlying mechanisms include an increase in energy 
expenditure, stimulation of fatty acid oxidation, and reduction of nutrient absorption [62]. The effects 
of GTCs whereby they suppress metabolic syndrome have also been investigated in laboratory, 
epidemiological, and intervention studies [63,64]. In a rodent model of obesity and diabetes, treatment 
with green tea or its constituents was found to result in significantly reduced body weight and, 
therefore, improved hyperglycemia, hyperinsulinemia, hyperleptinemia, hepatic steatosis, and liver 
dysfunction [65–67]. GTCs supplementation was also found to decrease plasma levels of insulin,   
TNF-α, and IL-6 in a rat insulin resistance model [68]. These reports suggest that long-term treatment 
with GTCs may be effective for preventing the progression of obesity-related metabolic disorders. 
In addition to the anti-obesity effects, GTCs possess anti-cancer and cancer-preventive   
properties [16–19]. Intervention studies provide clear evidence of the chemopreventive effects of   
tea preparations  [69,70]. A pilot study also showed that GTCs successfully prevent colorectal 
adenomas, the precancerous lesions of CRC, after polypectomy [71]. Several properties of GTCs   
are responsible for their anti-cancer and cancer-preventive effects, including their antioxidant and   
anti-inflammatory properties [16,72]. An increasing number of studies have reported that GTCs, 
especially the major biologically active component in green tea (−)-epigallocatechin gallate (EGCG), 
inhibit proliferation of and induce apoptosis among cancer cells by modulating the activities of 
different receptor tyrosine kinases (RTKs) and their downstream signaling pathways, including the 
Ras/extracellular signal-regulated kinase (ERK) and PI3K/Akt signaling pathways [17–19,73,74]. 
EGCG suppresses cell growth by inhibiting the activation of IGF-1R, a member of the RTK family, in 
human CRC and HCC cells, and this inhibition is associated with a decrease in the expression of   
IGF-1/2, but an increase in the expression of IGF-binding protein-3 (IGFBP-3), which negatively 
controls the function of the IGF/IGF-1R axis [49,75]. EGCG also prevents carbon tetrachloride-induced 
hepatic fibrosis in rats by inhibiting IGF-1R expression [76]. These reports indicate that the IGF/IGF-1R 
axis, which plays a critical role in both cancer development and obesity-induced pathological   
events [24,25], might be a critical target of GTCs. 
5. Preventive Effects of BCAA on Metabolic Abnormalities and HCC in Obese, Cirrhotic 
Patients: Results Form the LOTUS Study 
Because the liver, an important target organ of insulin, plays a critical role in regulating metabolism, 
patients with chronic liver diseases often suffer from several nutritional and metabolic disorders, such 
as protein-energy malnutrition and insulin resistance [77–80]. Decreased serum levels of BCAA and 
albumin are associated with a high incidence of liver cirrhosis, while supplementation with BCAA has Int. J. Mol. Sci. 2012, 13                 
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been shown to improve protein malnutrition and increase the serum albumin concentration in cirrhotic 
patients [20,77,78]. In addition, recent experimental studies have revealed that BCAA improves insulin 
resistance and glucose tolerance [81–83]. She et al. [81] reported that mitochondrial branched-chain 
aminotransferase knock out mice, which show a significant elevation in the serum BCAA level, exhibit 
decreased adiposity and remarkable improvements in glucose and insulin tolerance. BCAA has 
favorable effects on glucose metabolism not just in the liver but also in skeletal muscle and adipose 
tissue [84–86]. In the liver, BCAA activates liver-type glucokinase and glucose transporter (GLUT)-2, 
while suppressing the expression of glucose-6-phosphatase, which catalyzes the final steps of 
gluconeogenesis [84]. On the other hand, BCAA promotes glucose uptake through activation of PI3K 
and subsequent translocation of GLUT1 and GLUT4 to the plasma membrane in the skeletal 
muscle  [86]. Moreover, in mice fed a high-fat diet, BCAA supplementation ameliorated insulin 
resistance by improving adipocytokine imbalance, inhibiting lipid accumulation in the liver, and 
increasing the hepatic levels of peroxisome proliferator-activated receptor-α [87,88]. Several clinical 
trials have also reported that oral BCAA supplementation improves glucose tolerance and insulin 
resistance in patients with chronic liver disease [22,89,90]. 
The Long-Term Survival Study (LOTUS) was a large-scale (n = 622) multicenter randomized 
controlled trial conducted from 1997 to 2003 in Japan to investigate the effects of supplemental BCAA 
therapy on event-free survival in patients with decompensated cirrhosis. In this trial, oral 
supplementation with a BCAA preparation was found to significantly prevent progressive hepatic 
failure and improve event-free survival [20]. Moreover, subset analysis from this trial demonstrated 
that long-term oral supplementation with BCAA is associated with a reduced frequency of HCC in 
obese patients (BMI score ≥ 25, P = 0.008) with decompensated cirrhosis [8]. What could the 
mechanisms of action of BCAA in the prevention of HCC have been? It seems reasonable to consider 
that the improvement of glucose metabolism by BCAA contributes to a decrease in the HCC incidence 
in obese cirrhotic patients because these patients generally have a particularly high incidence of 
hyperinsulinemia and insulin resistance [79,80]. In addition, Hagiwara et al. [91] recently reported 
significant findings that BCAA suppresses insulin-induced proliferation of HCC cells by inhibiting the 
insulin-induced activation of the PI3K/Akt pathway and the subsequent anti-apoptotic pathway. The 
precise mechanisms of action of BCAA in relation to carcinogenesis are explained in detail in the 
following sections. 
6. Prevention of Obesity-Related CRC via the Nutraceutical Approach—GTCs and BCAA 
Effectively Prevent Obesity-Related Colorectal Carcinogenesis 
Recent evidence indicates that increased body fatness and BMI are associated with an increased risk 
of CRC [4,5,9–11]. In contrast, studies have provided convincing evidence that dietary habits, especially 
high fruit and vegetable consumption, may reduce the risk of this malignancy [92]. Hirose et al. [93] 
established a useful preclinical model to determine the underlying mechanisms of how specific agents 
prevent the development of obesity-related CRC. The model used was C57BL/KsJ-db/db (db/db) mice, 
which are a genetically altered animal model with phenotypes of obesity and diabetes mellitus [94]. 
These mice have hyperlipidemia, hyperinsulinemia, and hyperleptinemia and are susceptible to the 
colonic carcinogen azoxymethane (AOM) because AOM-induced colonic precancerous lesions, Int. J. Mol. Sci. 2012, 13                 
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aberrant crypt foci (ACF) and β-catenin accumulated crypts (BCAC), develop to a significantly greater 
extent in these mice than in the genetic control mice [93]. The colonic mucosa of db/db mice expresses 
high levels of IGF-1R, the phosphorylated (activated) form of IGF-1R (p-IGF-1R),  β-catenin,  
and cyclooxygenase-2 (COX-2) [95]. Dietary supplementation with certain types of flavonoids,   
such as citrus compounds, suppresses the development of these putative lesions for CRC in the db/db 
mice [96–98]. 
Figure 2. Mechanisms of action of green tea catechins (GTCs) and branched-chain amino 
acids (BCAA) in the inhibition of obesity-related colorectal carcinogenesis. 
 
We used this experimental model to investigate in detail the effects of EGCG and BCAA on the 
prevention of obesity-related colorectal carcinogenesis. We found that drinking water with EGCG 
significantly decreased the number of ACF and BCAC, which accumulate the IGF-1R protein, and this 
decrease was associated with inhibited expression of IGF-1R, p-IGF-1R, the phosphorylated form of 
glycogen synthase kinase-3β (GSK-3β), β-catenin, COX-2, and cyclin D1 on the colonic mucosa [95]. 
EGCG also increased the serum level of IGFBP-3 while decreasing the serum levels of IGF-1, insulin, 
triglycerides, total cholesterol, and leptin [95]. In accordance with this study, supplementation with 
BCAA also caused a significant reduction in the number of ACF and BCAC compared with the control 
diet-fed groups by inhibiting the phosphorylation of IGF-1R, GSK-3β, and Akt on the colonic 
mucosa [99]. The serum levels of insulin, IGF-1, IGF-2, triglycerides, total cholesterol, and leptin were 
also decreased [99]. These findings suggest that both EGCG and BCAA effectively suppress the 
development of premalignant CRC lesions by suppressing the IGF/IGF-1R axis; improving 
hyperlipidemia, hyperinsulinemia, and hyperleptinemia; and inhibiting the expression of COX-2, Int. J. Mol. Sci. 2012, 13                 
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which is involved in CRC development because it mediates inflammatory signaling pathways and can 
therefore be an important target for chemoprevention (Figure 2) [100]. 
7. Prevention of Obesity-Related HCC via the Nutraceutical Approach—BCAA and GTCs 
Effectively Prevent Obesity-Related Liver Carcinogenesis 
In addition to established risk factors such as hepatitis and alcohol consumption, obesity and its 
related metabolic abnormalities increase the risk of HCC [6–8,11]. NASH is also an important 
pathological condition when considering the prevention of obesity-related HCC because it progresses  
to cirrhosis and finally develops into HCC [53,54]. In order to elucidate the pathogenesis of obesity-  
and NASH-associated HCC and evaluate the mechanisms of how chemopreventive agents suppress   
these diseases, we developed a useful preclinical model using db/db mice and a liver carcinogen   
N-diethylnitrosamine (DEN) [101]. We found that db/db mice, which have severe steatosis, are more 
susceptible to DEN-induced liver tumorigenesis than the genetic control mice, and this oncogenic 
sensitivity is associated with the activation of the IGF/IGF-1R axis and induction of chronic 
inflammation in the liver [13,101–103]. 
Using this experimental model, we also investigated the possible inhibitory effects of BCAA and 
EGCG on obesity-related liver tumorigenesis. We found that BCAA supplementation significantly 
suppressed the development of hepatic preneoplastic lesions, known as foci of cellular alteration 
(FCA), in obese and diabetic db/db mice by inhibiting the expression of IGF-1, IGF-2, and IGF-1R in 
the liver [101]. The development of liver neoplasms, including hepatic adenoma and HCC, was   
also reduced by BCAA supplementation and this was associated with improvement of insulin 
resistance, reduction of serum levels of leptin, and attenuation of hepatic steatosis and fibrosis [101]. 
Yoshiji et al. [104] also reported that the chemopreventive effect exerted by BCAA supplementation 
against HCC in obese and diabetic rats was associated with the suppression of vascular endothelial 
growth factor expression and hepatic neovascularization. In addition, drinking water containing   
EGCG significantly inhibited the development of FCA and hepatic adenoma, and improved hepatic 
steatosis [103]. The serum levels of insulin, IGF-1, and IGF-2 and the phosphorylation of the IGF-1R, 
ERK, Akt, and GSK-3β proteins in the liver were reduced by EGCG consumption [103]. EGCG also 
decreased the levels of free fatty acids and TNF-α in the serum and the expression of TNF-α, IL-6, IL-1β, 
and IL-18 mRNAs in the liver, indicating that it prevents obesity-related liver tumorigenesis by inhibiting 
the IGF/IGF-1R axis, improving hyperinsulinemia, and attenuating chronic inflammation [103]. Thus, 
both BCAA and GTCs may be useful for the chemoprevention of liver carcinogenesis in obese 
individuals (Figure 3). Int. J. Mol. Sci. 2012, 13                 
 
 
587
Figure 3. Mechanisms of action of GTCs and BCAA in the inhibition of obesity-related 
liver carcinogenesis. 
 
8. Conclusions 
In the present social and medical circumstances, the consequences of obesity and its related 
metabolic abnormalities, including cancer, are critical issues that need to be resolved. Among human 
cancers, CRC and HCC are the most representative malignancies affected by obesity. In this review, 
we indicate the possibility that the nutraceutical approach for targeting and restoring metabolic 
homeostasis may be a promising strategy to prevent the development of obesity-related CRC and HCC. 
Tea catechins, especially GTCs, are considered one of the most practical agents for the prevention of 
obesity-related carcinogenesis because the safety and efficacy of GTCs as chemopreventive agents 
have been demonstrated in recent interventional trials [69,71]. BCAA is also a feasible agent because 
its preparations are widely used in clinical practice for patients with chronic liver diseases, and a 
randomized controlled trial has shown that BCAA supplementation can prevent HCC in such patients 
who are obese [8,20]. Thus, active intervention using GTCs and BCAA might be an effective approach 
for the chemoprevention of obesity-related CRC and HCC. 
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